218 related articles for article (PubMed ID: 24126537)
21. [Huntington chorea. Clinical correlations and preliminary neuropsychological data].
Fragassi NA; Stanzione M; Angelini R; Di Maio L
Acta Neurol (Napoli); 1992; 14(4-6):530-6. PubMed ID: 1293994
[TBL] [Abstract][Full Text] [Related]
22. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients.
Ribaï P; Nguyen K; Hahn-Barma V; Gourfinkel-An I; Vidailhet M; Legout A; Dodé C; Brice A; Dürr A
Arch Neurol; 2007 Jun; 64(6):813-9. PubMed ID: 17562929
[TBL] [Abstract][Full Text] [Related]
23. Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.
Hergert DC; Sanchez-Ramos J; Cimino CR
J Clin Exp Neuropsychol; 2015; 37(9):981-7. PubMed ID: 26332177
[TBL] [Abstract][Full Text] [Related]
24. Preparing for preventive clinical trials: the Predict-HD study.
Paulsen JS; Hayden M; Stout JC; Langbehn DR; Aylward E; Ross CA; Guttman M; Nance M; Kieburtz K; Oakes D; Shoulson I; Kayson E; Johnson S; Penziner E;
Arch Neurol; 2006 Jun; 63(6):883-90. PubMed ID: 16769871
[TBL] [Abstract][Full Text] [Related]
25. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
Huntington Study Group TREND-HD Investigators
Arch Neurol; 2008 Dec; 65(12):1582-9. PubMed ID: 19064745
[TBL] [Abstract][Full Text] [Related]
26. Neurodegenerative disease: Mapping the natural history of Huntington disease.
Barker RA; Mason SL
Nat Rev Neurol; 2014 Jan; 10(1):12-3. PubMed ID: 24323048
[No Abstract] [Full Text] [Related]
27. An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.
Vaccarino AL; Anderson K; Borowsky B; Duff K; Giuliano J; Guttman M; Ho AK; Orth M; Paulsen JS; Sills T; van Kammen DP; Evans KR;
Mov Disord; 2011 Apr; 26(5):877-84. PubMed ID: 21370269
[TBL] [Abstract][Full Text] [Related]
28. Earliest functional declines in Huntington disease.
Beglinger LJ; O'Rourke JJ; Wang C; Langbehn DR; Duff K; Paulsen JS;
Psychiatry Res; 2010 Jul; 178(2):414-8. PubMed ID: 20471695
[TBL] [Abstract][Full Text] [Related]
29. Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene.
Panegyres PK; Shu CC; Chen HY; Paulsen JS
J Neurol; 2015 Feb; 262(2):277-84. PubMed ID: 25380582
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
[TBL] [Abstract][Full Text] [Related]
31. Onset of Huntington's disease: can it be purely cognitive?
Paulsen JS; Long JD
Mov Disord; 2014 Sep; 29(11):1342-50. PubMed ID: 25142616
[TBL] [Abstract][Full Text] [Related]
32. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
[TBL] [Abstract][Full Text] [Related]
33. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
Cubo E; González M; del Puerto I; de Yébenes JG; Arconada OF; Gabriel y Galán JM;
Mov Disord; 2012 Mar; 27(3):439-42. PubMed ID: 22162184
[TBL] [Abstract][Full Text] [Related]
34. Rate of change in early Huntington's disease: a clinicometric analysis.
Meyer C; Landwehrmeyer B; Schwenke C; Doble A; Orth M; Ludolph AC;
Mov Disord; 2012 Jan; 27(1):118-24. PubMed ID: 22095693
[TBL] [Abstract][Full Text] [Related]
35. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM
Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067
[TBL] [Abstract][Full Text] [Related]
36. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.
Jacobs M; Hart EP; van Zwet EW; Bentivoglio AR; Burgunder JM; Craufurd D; Reilmann R; Saft C; Roos RA;
J Neurol; 2016 Oct; 263(10):2080-5. PubMed ID: 27435968
[TBL] [Abstract][Full Text] [Related]
37. Juvenile-onset huntington disease: a matter of perspective.
Biglan K; Shoulson I
Arch Neurol; 2007 Jun; 64(6):783-4. PubMed ID: 17562925
[No Abstract] [Full Text] [Related]
38. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.
Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW
Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053
[TBL] [Abstract][Full Text] [Related]
39. Rate of functional decline in Huntington's disease. Huntington Study Group.
Marder K; Zhao H; Myers RH; Cudkowicz M; Kayson E; Kieburtz K; Orme C; Paulsen J; Penney JB; Siemers E; Shoulson I
Neurology; 2000 Jan; 54(2):452-8. PubMed ID: 10668713
[TBL] [Abstract][Full Text] [Related]
40. Wheels within wheels: multifocal autoimmune myelitis in a woman with Huntington's disease.
Haghikia A; Décard BF; Hellwig K; Kraus P; Gold R
J Neurol; 2012 Sep; 259(9):1973-5. PubMed ID: 22460588
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
